We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eli Lilly said Tuesday that it expects earnings per share next year in the range of $6.70 to $6.80, with overall revenue between of $23.6 billion and $24.1 billion, driven by growth from key products such as Taltz and Trulicity.